FDA Approves Intravenous Formulation of Secukinumab FDA Approves Intravenous Formulation of Secukinumab

This new route of administration is expected to become available during the fourth quarter of 2023.Medscape Medical News

Source: Medscape Allergy Headlines - October 9, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news